Clinical Features and Prognostic Factors of 245 Portuguese Patients Hospitalized With COVID-19
Pedro Salvador, Pedro Oliveira, Tiago Costa, Mariana Fidalgo, Raul Neto, Maria Leonor Silva, Cristóvão Figueiredo, Vera Afreixo, Tiago Gregório, Luís Malheiro
Cureus, doi:10.7759/cureus.13687
Introduction Since the declaration of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in March 2020, Portugal was considered a role model with regards to the first COVID-19 wave. However, a third wave started in 2021 started, turning the country into the worst in the world regarding new infections and death rate per capita in the last weeks of January 2021. No significant data regarding the country's first wave of hospitalized patients have been published. Those data may help understand the differences over time regarding patients and the clinical approach to them. Herein, we present data of COVID-19 patients hospitalized at the main tertiary hospital of the second-most affected county at the time and identify risk factors associated with disease progression and outcomes.
Materials and methods We performed a prospective observational study of patients admitted with COVID-19 to a central hospital between March 20 and June 1, 2020. The primary endpoint of this study was 30-day mortality or the need for ventilatory support and the secondary outcomes were both outcomes individually.
Results 245 patients were included, with a median age of 79 years, 52% males. Hypertension (n = 172) and dyslipidemia (n = 114) were the most frequent comorbidities. Half of the patients (n = 121) were treated with hydroxychloroquine. The primary outcome occurred in 114 patients; mortality at 30 days was 35%. Age (OR 1.05; 1.02-1.07) and active cancer (OR 3.89; were associated with the primary outcome, with dyslipidemia being protective (OR 0.46; 0.25-0.80). Treatment with hydroxychloroquine or lopinavir/ritonavir was not associated with the main outcome. Patients who had been symptomatic for more than 7 days had lower mortality (OR 0.23; 0.09-0.63).
Discussion In the present study, age and cancer were associated with higher mortality, as noted in prior articles. The population had a higher median age than reported in previous studies, which may explain the increased mortality. The protective association of dyslipidemia was not previously described. This association was not related to statin intake.
Conclusion The reported high mortality of COVID-19 is rarely seen in other infectious diseases. Our elderly population probably reflects more reliably the incidence of COVID-19 in European countries with constricted age pyramids.
Additional Information Disclosures Human subjects: Consent was obtained or waived by all participants in this study. Comissão de Ética para a Saúde do Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE issued approval NA. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
References
Barochiner, Martinez, Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: a systematic review and meta-analysis, J Clin Pharm Ther,
doi:10.1111/jcpt.13246Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19 -preliminary report, N Engl J Med,
doi:10.1056/NEJMoa2007764Buitrago-Garcia, Egli-Gany, Counotte, Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis, PLoS Med,
doi:10.1371/journal.pmed.1003346Cai, Chen, Wang, Obesity and COVID-19 severity in a designated hospital in Shenzhen, China, Diabetes Care,
doi:10.2337/dc20-0576Cao, Wang, Wen, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2001282Cdc, People who are at higher risk for severe illness
Deng, Li, Zeng, Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study, J Infect,
doi:10.1016/j.jinf.2020.03.002Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949Levett, Raparelli, Mardigyan, Eisenberg, Cardiovascular pathophysiology, epidemiology, and treatment considerations of coronavirus disease, CJC Open,
doi:10.1016/j.cjco.2020.09.003Li, Huang, Zou, Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors and outcomes, J Med Virol,
doi:10.1002/jmv.26424Li, Xie, Lin, An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19, PREPPRINT,
doi:10.1101/2020.03.19.20038984Lim, Jeon, Shin, Case of the index patient who caused tertiary transmission of COVID-19 Infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR, J Korean Med Sci,
doi:10.3346/jkms.2020.35.e79Liu, Long, Xiong, Chen, Ma et al., Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: a rapid systematic review and meta-analysis, Clin Cardiol,
doi:10.1002/clc.23421Nasiri, Haddadi, Tahvildari, COVID-19 clinical characteristics, and sex-specific risk of mortality: systematic review and meta-analysis, Front Med,
doi:10.3389/fmed.2020.00459Pranata, Permana, Huang, The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis, Diabetes Metab Syndr,
doi:10.1016/j.dsx.2020.06.047Prasad, Panhwar, Hendel, COVID-19 and the cardiovascular system: a review of current data, summary of best practices, outline of controversies, and illustrative case reports, Am Heart J,
doi:10.1016/j.ahj.2020.06.009Siddiqi, Mehra, COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal, J Heart Lung Transplant,
doi:10.1016/j.healun.2020.03.012Wang, Chen, Lu, Chen, Zhang, Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment, Biosci Trends,
doi:10.5582/bst.2020.01030Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet,
doi:10.1016/s0140-6736(20)31022-9Who, Weekly epidemiological update -2
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA,
doi:10.1001/jama.2020.2648DOI record:
{
"DOI": "10.7759/cureus.13687",
"ISSN": [
"2168-8184"
],
"URL": "http://dx.doi.org/10.7759/cureus.13687",
"author": [
{
"affiliation": [],
"family": "Salvador",
"given": "Pedro",
"sequence": "first"
},
{
"affiliation": [],
"family": "Oliveira",
"given": "Pedro",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Costa",
"given": "Tiago",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Fidalgo",
"given": "Mariana",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Neto",
"given": "Raul",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Silva",
"given": "Maria Leonor",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Figueiredo",
"given": "Cristóvão",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Afreixo",
"given": "Vera",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Gregório",
"given": "Tiago",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Malheiro",
"given": "Luís",
"sequence": "additional"
}
],
"container-title": "Cureus",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
3,
4
]
],
"date-time": "2021-03-04T09:26:00Z",
"timestamp": 1614849960000
},
"deposited": {
"date-parts": [
[
2024,
2,
9
]
],
"date-time": "2024-02-09T19:24:57Z",
"timestamp": 1707506697000
},
"indexed": {
"date-parts": [
[
2024,
2,
10
]
],
"date-time": "2024-02-10T00:17:46Z",
"timestamp": 1707524266397
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2021,
3,
4
]
]
},
"language": "en",
"link": [
{
"URL": "https://www.cureus.com/articles/53247-clinical-features-and-prognostic-factors-of-245-portuguese-patients-hospitalized-with-covid-19",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "297",
"original-title": [],
"prefix": "10.7759",
"published": {
"date-parts": [
[
2021,
3,
4
]
]
},
"published-print": {
"date-parts": [
[
2021,
3,
4
]
]
},
"publisher": "Springer Science and Business Media LLC",
"reference": [
{
"key": "ref1",
"unstructured": "Saúde DGd. Relatório de Situação nº 091 | 01/06/2020. (2020). Accessed. July 7, 2020: https://covid19.min-saude.pt/wp-content/uploads/2020/06/91_DGS_boletim_20200601.pdf."
},
{
"key": "ref2",
"unstructured": "WHO. Weekly epidemiological update - 2 February 2021. (2021). Accessed. February 14, 2021: https://www.who.int/publications/m/item/weekly-epidemiological-update---2-february-2021."
},
{
"DOI": "10.1016/j.clim.2020.108427",
"article-title": "COVID-19 pathophysiology: a review",
"author": "Yuki K",
"doi-asserted-by": "publisher",
"journal-title": "Clin Immunol",
"key": "ref3",
"unstructured": "Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol. 2020, 215:108427. 10.1016/j.clim.2020.108427",
"volume": "215",
"year": "2020"
},
{
"DOI": "10.1080/00325481.2020.1823094",
"article-title": "Multisystem effects of COVID- 19: a concise review for practitioners",
"author": "White-Dzuro G",
"doi-asserted-by": "publisher",
"journal-title": "Postgrad Med",
"key": "ref4",
"unstructured": "White-Dzuro G, Gibson LE, Zazzeron L, et al.. Multisystem effects of COVID- 19: a concise review for practitioners. Postgrad Med. 2021, 133:20-27. 10.1080/00325481.2020.1823094",
"volume": "133",
"year": "2021"
},
{
"DOI": "10.1016/j.healun.2020.03.012",
"article-title": "COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal",
"author": "Siddiqi HK",
"doi-asserted-by": "publisher",
"journal-title": "J Heart Lung Transplant",
"key": "ref5",
"unstructured": "Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020, 39:405-407. 10.1016/j.healun.2020.03.012",
"volume": "39",
"year": "2020"
},
{
"DOI": "10.1001/jama.2020.2648",
"article-title": "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention",
"author": "Wu Z",
"doi-asserted-by": "publisher",
"journal-title": "JAMA",
"key": "ref6",
"unstructured": "Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020, 323:1239-1242. 10.1001/jama.2020.2648",
"volume": "323",
"year": "2020"
},
{
"DOI": "10.1016/s0140-6736(20)30183-5",
"article-title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",
"author": "Huang C",
"doi-asserted-by": "publisher",
"journal-title": "Lancet",
"key": "ref7",
"unstructured": "Huang C, Wang Y, Li X, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395:497-506. 10.1016/s0140-6736(20)30183-5",
"volume": "395",
"year": "2020"
},
{
"DOI": "10.1371/journal.pmed.1003346",
"article-title": "Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis",
"author": "Buitrago-Garcia D",
"doi-asserted-by": "publisher",
"journal-title": "PLoS Med",
"key": "ref8",
"unstructured": "Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al.. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med. 2020, 17:1003346. 10.1371/journal.pmed.1003346",
"volume": "17",
"year": "2020"
},
{
"key": "ref9",
"unstructured": "CDC. People who are at higher risk for severe illness. (2021). Accessed. February 14, 2021: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html."
},
{
"DOI": "10.3760/cma.j.issn.0254-6450.2020.02.003",
"article-title": "The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [Article in Chinese]",
"author": "Epidemiology Working Group for NCIP Epidemic Response",
"doi-asserted-by": "publisher",
"journal-title": "Zhonghua Liu Xing Bing Xue Za Zhi",
"key": "ref10",
"unstructured": "Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [Article in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020, 41:145-151. 10.3760/cma.j.issn.0254-6450.2020.02.003",
"volume": "41",
"year": "2020"
},
{
"DOI": "10.3389/fmed.2020.00459",
"article-title": "COVID-19 clinical characteristics, and sex-specific risk of mortality: systematic review and meta-analysis",
"author": "Nasiri MJ",
"doi-asserted-by": "publisher",
"journal-title": "Front Med (Lausanne)",
"key": "ref11",
"unstructured": "Nasiri MJ, Haddadi S, Tahvildari A, et al.. COVID-19 clinical characteristics, and sex-specific risk of mortality: systematic review and meta-analysis. Front Med (Lausanne). 2020, 7:459. 10.3389/fmed.2020.00459",
"volume": "7",
"year": "2020"
},
{
"DOI": "10.1016/j.cjco.2020.09.003",
"article-title": "Cardiovascular pathophysiology, epidemiology, and treatment considerations of coronavirus disease",
"author": "Levett JY",
"doi-asserted-by": "publisher",
"journal-title": "CJC Open",
"key": "ref12",
"unstructured": "Levett JY, Raparelli V, Mardigyan V, Eisenberg MJ. Cardiovascular pathophysiology, epidemiology, and treatment considerations of coronavirus disease. CJC Open. 2019, 19:28-40. 10.1016/j.cjco.2020.09.003",
"volume": "19",
"year": "2019"
},
{
"DOI": "10.1016/j.dsx.2020.06.047",
"article-title": "The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID- 19): a systematic review and meta-analysis",
"author": "Pranata R",
"doi-asserted-by": "publisher",
"journal-title": "Diabetes Metab Syndr",
"key": "ref13",
"unstructured": "Pranata R, Permana H, Huang I, et al.. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID- 19): a systematic review and meta-analysis. Diabetes Metab Syndr. 2020, 14:983-990. 10.1016/j.dsx.2020.06.047",
"volume": "14",
"year": "2020"
},
{
"DOI": "10.1002/clc.23421",
"article-title": "Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: a rapid systematic review and meta-analysis",
"author": "Liu X",
"doi-asserted-by": "publisher",
"journal-title": "Clin Cardiol",
"key": "ref14",
"unstructured": "Liu X, Long C, Xiong Q, Chen C, Ma J, Su Y, Hong K. Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: a rapid systematic review and meta-analysis. Clin Cardiol. 2020, [Epub ahead of print]:10.1002/clc.23421",
"volume": "[Epub ahead of print]",
"year": "2020"
},
{
"DOI": "10.1111/jcpt.13246",
"article-title": "Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: a systematic review and meta-analysis",
"author": "Barochiner J",
"doi-asserted-by": "publisher",
"journal-title": "J Clin Pharm Ther",
"key": "ref15",
"unstructured": "Barochiner J, Martinez R. Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: a systematic review and meta-analysis. J Clin Pharm Ther. 2020, 45:1244-1252. 10.1111/jcpt.13246",
"volume": "45",
"year": "2020"
},
{
"DOI": "10.1016/j.ahj.2020.06.009",
"article-title": "COVID-19 and the cardiovascular system: a review of current data, summary of best practices, outline of controversies, and illustrative case reports",
"author": "Prasad A",
"doi-asserted-by": "publisher",
"journal-title": "Am Heart J",
"key": "ref16",
"unstructured": "Prasad A, Panhwar S, Hendel RC, et al.. COVID-19 and the cardiovascular system: a review of current data, summary of best practices, outline of controversies, and illustrative case reports. Am Heart J. 2020, 226:174-187. 10.1016/j.ahj.2020.06.009",
"volume": "226",
"year": "2020"
},
{
"DOI": "10.2337/dc20-0576",
"article-title": "Obesity and COVID-19 severity in a designated hospital in Shenzhen, China",
"author": "Cai Q",
"doi-asserted-by": "publisher",
"journal-title": "Diabetes Care",
"key": "ref17",
"unstructured": "Cai Q, Chen F, Wang T, et al.. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020, 43:1392-1398. 10.2337/dc20-0576",
"volume": "43",
"year": "2020"
},
{
"DOI": "10.1101/2020.04.08.20057794",
"article-title": "Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City [PREPRINT]",
"author": "Petrilli CM",
"doi-asserted-by": "publisher",
"journal-title": "medRxiv",
"key": "ref18",
"unstructured": "Petrilli CM, Jones SA, Yang J, et al.. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City [PREPRINT]. medRxiv. 2020, 10.1101/2020.04.08.20057794",
"year": "2020"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105949",
"article-title": "Hydroxychloroquine and azithromycin as a treatment of COVID- 19: results of an open-label non-randomized clinical trial",
"author": "Gautret P",
"doi-asserted-by": "publisher",
"journal-title": "Int J Antimicrob Agents",
"key": "ref19",
"unstructured": "Gautret P, Lagier JC, Parola P, et al.. Hydroxychloroquine and azithromycin as a treatment of COVID- 19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020, 56:105949. 10.1016/j.ijantimicag.2020.105949",
"volume": "56",
"year": "2020"
},
{
"DOI": "10.1016/j.jinf.2020.03.002",
"article-title": "Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study",
"author": "Deng L",
"doi-asserted-by": "publisher",
"journal-title": "J Infect",
"key": "ref20",
"unstructured": "Deng L, Li C, Zeng Q, et al.. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Infect. 2020, 81:1-5. 10.1016/j.jinf.2020.03.002",
"volume": "81",
"year": "2020"
},
{
"DOI": "10.3346/jkms.2020.35.e79",
"article-title": "Case of the index patient who caused tertiary transmission of COVID-19 Infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR",
"author": "Lim J",
"doi-asserted-by": "publisher",
"journal-title": "J Korean Med Sci",
"key": "ref21",
"unstructured": "Lim J, Jeon S, Shin HY, et al.. Case of the index patient who caused tertiary transmission of COVID-19 Infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020, 35:e79. 10.3346/jkms.2020.35.e79",
"volume": "35",
"year": "2020"
},
{
"DOI": "10.5582/bst.2020.01030",
"article-title": "Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment",
"author": "Wang Z",
"doi-asserted-by": "publisher",
"journal-title": "Biosci Trends",
"key": "ref22",
"unstructured": "Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020, 14:64-68. 10.5582/bst.2020.01030",
"volume": "14",
"year": "2020"
},
{
"key": "ref23",
"unstructured": "Recovery trial. (2020). Accessed. February 14, 2021: https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-th...."
},
{
"DOI": "10.1056/NEJMoa2001282",
"article-title": "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19",
"author": "Cao B",
"doi-asserted-by": "publisher",
"journal-title": "N Engl J Med",
"key": "ref24",
"unstructured": "Cao B, Wang Y, Wen D, et al.. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020, 382:1787-1799. 10.1056/NEJMoa2001282",
"volume": "382",
"year": "2020"
},
{
"DOI": "10.1101/2020.03.19.20038984",
"article-title": "An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) [PREPPRINT]",
"author": "Li Y",
"doi-asserted-by": "publisher",
"journal-title": "medRxiv",
"key": "ref25",
"unstructured": "Li Y, Xie Z, Lin W, et al.. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) [PREPPRINT]. medRxiv. 2020, 10.1101/2020.03.19.20038984",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2021436",
"article-title": "Dexamethasone in hospitalized patients with Covid-19",
"author": "The RECOVERY Collaborative Group",
"doi-asserted-by": "publisher",
"journal-title": "N Engl J Med",
"key": "ref26",
"unstructured": "The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2020, 384:693-704. 10.1056/NEJMoa2021436",
"volume": "384",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2007764",
"article-title": "Remdesivir for the treatment of Covid-19 - preliminary report",
"author": "Beigel JH",
"doi-asserted-by": "publisher",
"journal-title": "N Engl J Med",
"key": "ref27",
"unstructured": "Beigel JH, Tomashek KM, Dodd LE, et al.. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med. 2020, 383:1813-1826. 10.1056/NEJMoa2007764",
"volume": "383",
"year": "2020"
},
{
"DOI": "10.1016/s0140-6736(20)31022-9",
"article-title": "Remdesivir in adults with severe COVID- 19: a randomised, double-blind, placebo-controlled, multicentre trial",
"author": "Wang Y",
"doi-asserted-by": "publisher",
"journal-title": "Lancet",
"key": "ref28",
"unstructured": "Wang Y, Zhang D, Du G, et al.. Remdesivir in adults with severe COVID- 19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020, 395:1569-1578. 10.1016/s0140-6736(20)31022-9",
"volume": "395",
"year": "2020"
},
{
"DOI": "10.1002/jmv.26424",
"article-title": "Epidemiology of COVID- 19: a systematic review and meta-analysis of clinical characteristics, risk factors and outcomes",
"author": "Li J",
"doi-asserted-by": "publisher",
"journal-title": "J Med Virol",
"key": "ref29",
"unstructured": "Li J, Huang DQ, Zou B, et al.. Epidemiology of COVID- 19: a systematic review and meta-analysis of clinical characteristics, risk factors and outcomes. J Med Virol. 2020, 93:1449-1458. 10.1002/jmv.26424",
"volume": "93",
"year": "2020"
},
{
"article-title": "Population Aging in Europe. Facts, Implications, and Policies",
"author": "Commission E",
"key": "ref30",
"unstructured": "Commission E. Population Aging in Europe. Facts, Implications, and Policies. European Commission, Belgium; 2014.",
"year": "2014"
}
],
"reference-count": 30,
"references-count": 30,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.cureus.com/articles/53247-clinical-features-and-prognostic-factors-of-245-portuguese-patients-hospitalized-with-covid-19"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Aerospace Engineering"
],
"subtitle": [],
"title": "Clinical Features and Prognostic Factors of 245 Portuguese Patients Hospitalized With COVID-19",
"type": "journal-article"
}
